Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b

doi:10.3748/wjg.v19.i31.5067

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 31

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6197)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

382

HTML

3317

Figures (1-4)

281

Tables (1-4)

216

Sum=4196

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

971

Download

1030

Sum=2001

Aug 21, 2013 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Aug 21, 2013; 19(31): 5067-5075
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5067

Table 4 Serum levels of proteins after 24 wk of treatment in the sustained virological responders and non-responders

Spot	Protein Name	NCBI ID	MW/pI	No. of match peptide	MS score	Fold change	∆ relative intensity	Biological function
Sustained virological response
38	Proapolipoprotein	Gi\|178775	28.94/5.50	63	798	↑ 5.17	0.1525^a	Cholesterolmetabolism
26	Chain A, the structure of pentameric human serum amyloid P	Gi\|576259	23.36/6.12	12	174	↑ 6.65	0.0783^a	Acute phase protein
86	Alpha-2-HS-glycoprotein	Gi\|112910	40.098/5.43	32	494	↑ 2.39	0.3773^a
309	Alpha-2-HS-glycoprotein	Gi\|112910	40.09/5.43	29	507	↑ 2.04	0.4987^a
171	Chain A, the intact and cleaved III complex as a model for serpin-proteinase interaction	Gi\|999513	49.35/5.95	37	396	↑ 9.66	0.1481^b
173	Chain A, the intact and cleaved III complex as a model for serpin-proteinase interaction	Gi\|999513	49.35/5.95	26	210	↑ 8.01	0.0694^a	Protease inhibitor
149	Serotransferin precursor	Gi\|4557871	79.28/6.81	58	650	↑ 3.43	0.1165^a
201	PRO2619	Gi\|11493459	58.51/5.96	36	278	↑ 4.95	0.0594^a	Transport protein and proteinbinding
207	Albumin	Gi\|332356380	68.48/5.73	48	781	↑ 6.97	0.1653^a
280	Albumin	Gi\|332356380	68.48/5.73	31	201	↑ 7.33	0.1206^a
202	CD5 antigen-like precursor	Gi\|5174411	39.60/5.28	11	70	↑ absent at baseline	0.0348^a
229	Ig J-chain	Gi\|532598	16.04/4.62	3	42	↑ absent at baseline	0.0923^b	Immunity protection
299	Immunoglobulin light	Gi\|218783338	24.16/5.95	26	747	↑ absent at base line	0.1709^b
Non-responder
20	Proapolipoprotein	Gi\|178775	28.94/5.45	63	798	↑ absent at base line	0.2383^b	Cholesterol metabolism
171	Chain A, the intact and cleaved III complex as a model for serpine-proteinase interaction	Gi\|999513	49.35/5.95	37	396	↑ 2.39	0.0896^a	Acute phase protein
4	Albumin isoform	Gi\|119626066	27.67/6.39	20	660	↓ 0.04	-0.2832^a	Transport protein and protein binding
264	Serum albumin	Gi\|62113341	71.09/5.85	21	115	↓ absent at 24 wk	-0.1196^a
123	Alpha-1-B-glycoprotein	Gi\|69990	52.47/5.69	27	247	↑ 1.38	0.1610^a	Serum protein
310	Alpha-2-HS-glycoprotein	Gi\|112910	40.09/5.43	30	475	↓ 0.46	-0.4119^a	Acute phase protein

Relative intensity, [(volume of spot/volume of all the spots in the gel) × 100].

^aP < 0.05,

^bP < 0.01 vs relative intensity.

Citation: Kuakarn S, SomParn P, Tangkijvanich P, Mahachai V, Thongboonkerd V, Hirankarn N. Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b. World J Gastroenterol 2013; 19(31): 5067-5075
URL: https://www.wjgnet.com/1007-9327/full/v19/i31/5067.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i31.5067